title: Tamoxifen enhances the control of acromegaly treated with somatostatin analog lanreotide.
abstract: We present the case of a 51-year old female patient with acromegaly that was resistant to somatostatin analogs and dopamine agonists. The patient was diagnosed with breast cancer requiring treatment with the anti-estrogen tamoxifen. Prior to initiating the treatment with tamoxifen, the IGF-I level was very high at 415% of the upper limit of normal for the patient's age and sex. During the tamoxifen treatment, the level of IGF-I dropped spectacularly down to normal levels. This observation highlights the effect of an anti-estrogen treatment in certain female patients with acromegaly.
authors.affiliation: Department of Endocrinology and Metabolic Diseases, CHU Larrey, 24 Chemin de Pourvouville, TSA 30030, 31059, Toulouse Cedex 9, France.
authors.forename: Jean-Christophe
authors.initials: JC
authors.lastname: Maiza
authors.forename: Stéphane
authors.initials: S
authors.lastname: Castillo-Ros
authors.forename: Maria
authors.initials: M
authors.lastname: Matta
authors.forename: Antoine
authors.initials: A
authors.lastname: Bennet
authors.forename: Philippe
authors.initials: P
authors.lastname: Caron
mesh_terms: D000172:Acromegaly / Q000188:drug therapy* / Q000378:metabolism; D005260:Female; D006801:Humans; D007334:Insulin-Like Growth Factor I / Q000378:metabolism; D008875:Middle Aged; D010456:Peptides, Cyclic / Q000627:therapeutic use*; D013004:Somatostatin / Q000031:analogs & derivatives* / Q000627:therapeutic use*; D013629:Tamoxifen / Q000627:therapeutic use
chemical_list: D010456:Peptides, Cyclic; D013629:Tamoxifen; C060347:lanreotide; D013004:Somatostatin; D007334:Insulin-Like Growth Factor I